Navigation Links
Drug trial results refine treatment during angioplasty operations
Date:8/31/2010

nt the results of the FUTURA-OASIS 8 (Fondaparinux with UnfracTionated heparin dUring Revascularisation in Acute coronary syndromes) trial at the annual European Society of Cardiology Congress in Stockholm, Sweden on August 31. The study was also published simultaneously in the Journal of the American Medical Association (JAMA).

FUTURA-OASIS 8 is a Phase III, multicentre, multinational, randomized, parallel-group trial of 2,026 patients undergoing angioplasty within 72 hours of arriving in a hospital with unstable angina or a heart attack. As soon as possible after their arrival, patients were enrolled and received fondaparinux 2.5 mg daily. Patients who required angioplasty were then randomized to low fixed dose heparin or standard dose heparin with activated clotting time (ACT) guidance during angioplasty. The low fixed dose UFH regimen consisted of a dose of 50 U/kg irrespective of use of GP IIb/IIIa inhibitors (another group of drugs used to prevent clots at time of angioplasty). The standard dose UFH regimen consisted of a dose of 85 U/kg or 60 U/kg when GP IIb/IIIa inhibitor used, adjusted by blinded ACT.

The low dose regimen did not reduce the risk of major or minor bleeding or vascular access complications compared to standard dose regimen. The low dose regimen did not lower the risk of major bleeding but did lower minor bleeding by 60 per cent. There was a trend, however, for higher risk of death, myocardial infarction or target vessel revascularization with low dose vs. standard dose UFH. The rates of catheter thrombosis were very low (0.5 per cent and 0.1 per cent in the low and standard dose UFH groups). In the standard dose arm, only about one in five patients required an additional UFH bolus to reach target ACT.

"There has been a widely believed hypothesis that lowering heparin dose lowers bleeding with similar efficacy during angioplasty but randomized trial data has been lacking," remarked Professor Gabriel Steg, int
'/>"/>

Contact: Laura Thompson
lthomp@mcmaster.ca
905-525-9140
McMaster University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Success stops drug trial
2. In Early Trial, Targeted Therapy Fights Advanced Melanoma
3. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
4. Decade-long trial confirms benefts of steroid withdrawal for transplant patients
5. Trial Therapy Improves Melanoma Survival
6. CRF announces featured clinical trials to be presented at TCT 2010
7. Clinical trials: Comprehension unaffected by simplified consent forms or payment
8. Clinical trials abroad: Making non-English language consent forms readable
9. Human clinical trial of NIH-developed dengue vaccine begins
10. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
11. Drug trials funded by industry are more likely to publish favorable results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Zereana Jess-Huff, a 34-year-old mother, corporate ... on a platform to think outside the bra. She doesn’t ... position to raise awareness about women’s other lady parts. , ... You say the color pink and everybody knows what you’re ... fact that it has not been won when it comes ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Sit and Slim II . , The ... use Sit and Slim II because it contains Sibutramine ... weight loss product on various websites and possibly in some ... for safety reasons, can significantly increase blood pressure and/or pulse ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Rockynol ... Living Center on Oct. 14. The $11 million project ... services, and a cooked-to-order kitchen with full-service restaurant style ... premier choice for first class Assisted Living apartments,” said ... residents deserve the highest quality of care and this ...
(Date:10/20/2014)... Based on a proprietary chromatid-specific ... assays capable of determining DNA sequence, location and ... three dimensions of high-resolution data, dGH assays are ... range of disease-causing genetic rearrangements, including chromosomal inversions ... tools, including today’s advanced sequencing technologies. , According ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3
... his arms in an accident is getting some high-tech help ... ,Two years ago, a healthy Jesse Sullivan, 56, ... touched a live wire,// costing him both his arms up ... with a traditional artificial prosthesis, relying on chains and buttons ...
... of using a bell and meat powder, which is what ... intrinsic significance and coupled those to food smells," said Dr. ... ,Gottfried was trying to explain what he calls the "restaurant ... your birthday and you have gone though all the appetizers ...
... but gold can. In a remarkable experiment, Indian scientists have developed ... as the 'factory'. ,But before rushing to try cultivating fig trees ... caution : The scientists have been able to use the micro- ... human hair.// ,And therein lies the beauty of the new gold. ...
... Polycystic Ovarian Syndrome(PCOS),a condition which affects women of child-bearing ... testosterone, the so-called male hormone, rendering them unable to ... of facial hair, though scientists have said women// without ... also are a PCOS trait, though women's health experts ...
... one of the most exquisite pieces of engineering in the ... vulnerable to a debilitating degeneration as a result of the ... to blindness. These parts have to be kept from wearing ... lifetime. This, researchers have found, is possible through nutrients that ...
... accompanied by visual disturbances as well as sensitivity ... respond to a drug hitherto used to treat ... that drugs like candesartan cilexetil (Atacand) reduces the ... team decided to study Atacand after a colleague ...
Cached Medicine News:Health News:A man who lost both of his arms in an accident 2Health News:Brain scans show why we always have room for dessert 2Health News:Cultivating gold on a fig tree 2Health News:Polycystic Ovarian Syndrome(PCOS) linked to Diabetes 2Health News:Drug used to treat hypertension effective in countering Migraines 2
(Date:10/18/2014)... 2014  In a policy paper ... nation,s largest lesbian, gay, bisexual and transgender (LGBT) ... Truvada for Pre-Exposure Prophylaxis (PrEP). PrEP is any ... the spread of a disease or infection prior ... anti-HIV drug combination currently approved for PrEP, which ...
(Date:10/17/2014)... AUSTIN, Texas , Oct. 17, 2014  Hanger, ... it plans to report its results of operations for ... 6, 2014 after the market closes.  A conference call ... 9:00 a.m., ET, on Friday, November 7, 2014. Those ... be available until Friday, November 14, 2014 by dialing ...
(Date:10/17/2014)... Research ... addition of the  "China Interventional Cardiovascular Device ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The ... China impacted by accelerated aging ... dietary habit, way of working and other ...
Breaking Medicine Technology:HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3
... DIEGO , May 6 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... financial results for the first quarter ended March 31, 2010 on ... followed by a live webcast and conference call at 5:00 p.m. Eastern ... Orexigen management will ...
... , May 6 DUSA Pharmaceuticals, Inc. ( DUSA ) announces that its corporate ... 6:30 a.m. to be followed by a conference call at 8:30 a.m. , ... - 8:30 a.m. E.T. , , , ... , , 800-647-4314 , ...
Cached Medicine Technology:Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010 2DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: